ClinicalTrials.gg
CompletedNCT05325931Updated Aug 6, 2026Results posted

1-Week Dispensing Evaluation of Kalifilcon A Daily Disposable Multifocal Compared to Ultra for Presbyopia

An interventional study of kalifilcon A Daily Disposable Multifocal and samfilcon A for Presbyopia in Presbyopia, sponsored by Bausch & Lomb Incorporated. Completed at 1 site in United States. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Bausch & Lomb Incorporated (part of Bausch Health Companies Inc.) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 26 studies in Presbyopia by Bausch Health Companies Inc. — 2 open to participants now, 2 under way, none of them phase 3. Presbyopia · Bausch Health Companies Inc..

Enrollment
19th of 20
30 · median 99
Started
2022
with 3 others
No phase
12 of 26
none open now
Registered
21st of 26
by date

Among the 26 studies in Presbyopia by Bausch Health Companies Inc., this one is the 19th largest by enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2022, is one of 12 with no phase, and was the 21st registered.

Presbyopia

336 studies on the registry are indexed under Presbyopia; 35 are open to participants now.

Browse Presbyopia studies →

Open to participants now

2 of the 26 studies in Presbyopia by Bausch Health Companies Inc. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 20 Presbyopia studies recruiting now, 7 (35%) set no upper age limit and 11 (55%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.

This study: 40 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Presbyopia by Bausch Health Companies Inc., or all of them as a file.
02

Study summary

Experienced soft contact lens wearing subjects will be enrolled in this 1-week, confirmatory, randomized, bilateral, 2-way crossover, double masked (subject and investigator), repeated measures, dispensing study. All subjects will be seen for a Screening/Dispensing Visit at which informed consent will be obtained and eligibility will be assessed. If subjects satisfy all eligibility criteria and none of the exclusion criteria, subjects will be fit and dispensed study lenses according to unique randomization schedules that will be provided to each Investigator If vision is unsatisfactory in the original dispensed lenses, additional lens powers may be trialed.

03

Conditions studied

  • Presbyopia

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be 40 years or older on the date the Form (ICF) is signed and have the capacity to read, understand and provide written voluntary informed consent.
  • Have physiologically normal anterior segments not exhibiting biomicroscopy findings.
  • Have no active ocular disease or allergic conjunctivitis.
  • Not be using any topical ocular medications.
  • Be willing and able to follow instructions.
  • Have signed a statement of informed consent.

Exclusion criteria

Exclusion Criteria:

  • Participating in a conflicting study.
  • Considered by the Investigator to not be a suitable candidate for participation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    kalifilcon A First, Then samfilcon A for Presbyopia

    Participants wore kalifilcon A Daily Disposable Multifocal (Low Add and High Add) lenses bilaterally, daily-disposable/single-use, for approximately 1 week, then crossed over to Ultra for Presbyopia (samfilcon A) Low and High Add lenses bilaterally, daily-disposable, for approximately 1 week.

    Device: kalifilcon A Daily Disposable Multifocal · Device: samfilcon A for Presbyopia

  • Experimental
    samfilcon A for Presbyopia First, Then kalifilcon A

    Participants wore Ultra for Presbyopia (samfilcon A) Low and High Add lenses bilaterally, daily-disposable/single-use, for approximately 1 week, then crossed over to kalifilcon A Daily Disposable Multifocal (Low Add and High Add) lenses bilaterally, daily-disposable, for approximately 1 week.

    Device: kalifilcon A Daily Disposable Multifocal · Device: samfilcon A for Presbyopia

Interventions

  • Devicekalifilcon A Daily Disposable Multifocal

    kalifilcon A Daily Disposable Multifocal contact lenses (Low Add \[LD191001\] and High Add \[LD191002\] designs), worn bilaterally on a daily-disposable, single-use basis (≥8 hours/day) for approximately 1 week.

  • Devicesamfilcon A for Presbyopia

    Ultra for Presbyopia (samfilcon A) Low and High Add contact lenses, worn bilaterally on a daily-disposable, single-use basis (≥8 hours/day) for approximately 1 week.

06

What researchers measure

Primary outcomes

  1. Visual Acuity (Distance)

    Mean Binocular logMAR Visual Acuity at Distance (6m)

    Time frame: One week (follow-up visit)

  2. Visual Acuity (Near)

    Mean Binocular logMAR Visual Acuity at Near (40cm)

    Time frame: One week (follow-up)

07

Results

Posted Aug 6, 2026
Limitations and caveats
single-site

Participant flow

30 patients were screened for eligibility between February 25, 2022 and March 15, 2022.

First Intervention (1 Week)
Participant flow — First Intervention (1 Week)
MilestoneKalifilcon A Daily Disposable Multifocal First, Then Samfilcon A for PresbyopiaSamfilcon A for Presbyopia First, Then Kalifilcon A Daily Disposable Multifocal
Started1515
Completed1515
Not completed00
Second Intervention (1 Week)
Participant flow — Second Intervention (1 Week)
MilestoneKalifilcon A Daily Disposable Multifocal First, Then Samfilcon A for PresbyopiaSamfilcon A for Presbyopia First, Then Kalifilcon A Daily Disposable Multifocal
Started1515
Completed1514
Not completed01
Withdrew: Lost to follow-up01

Outcome measures

PrimaryVisual Acuity (Distance)

Mean Binocular logMAR Visual Acuity at Distance (6m)

Time frame:
One week (follow-up visit)
Reported as:
Mean · logMAR
Visual Acuity (Distance)
logMARKalifilcon A Daily Disposable Multifocal (Test)Ultra (Samfilcon A) for Presbyopia (Comparator)
Visual Acuity (Distance)-0.091 ± 0.0788-0.074 ± 0.0691
Statistical analysis
  • Kalifilcon A Daily Disposable Multifocal (Test) vs Ultra (Samfilcon A) for Presbyopia (Comparator) · t-test, 1 sided · p = <0.001 · Mean difference (final values): -0.017Mean difference (Test minus Comparator) in binocular logMAR visual acuity at distance (6m) from the two-period crossover, with the one-sided 97.5% upper confidence bound. The pre-specified non-inferiority margin was 0.06 logMAR.
PrimaryVisual Acuity (Near)

Mean Binocular logMAR Visual Acuity at Near (40cm)

Time frame:
One week (follow-up)
Reported as:
Mean · logMAR
Visual Acuity (Near)
logMARKalifilcon A Daily Disposable Multifocal (Test)Ultra (Samfilcon A) for Presbyopia (Comparator)
Visual Acuity (Near)0.179 ± 0.16790.182 ± 0.1771
Statistical analysis
  • Kalifilcon A Daily Disposable Multifocal (Test) vs Ultra (Samfilcon A) for Presbyopia (Comparator) · t-test, 1 sided · p = <0.001 · Mean difference (final values): -0.003Mean difference (Test minus Comparator) in binocular logMAR visual acuity at near (40cm) from the two-period crossover, with the one-sided 97.5% upper confidence bound. The pre-specified non-inferiority margin was 0.06 logMAR.

Adverse events

Collected over Approximately 2 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Kalifilcon A Multifocal (Test)0/30 (0%)0/30 (0%)0/30 (0%)
Ultra (Samfilcon A) for Presbyopia (Comparator)0/30 (0%)0/30 (0%)0/30 (0%)

Baseline characteristics

One participant was discontinued / lost to follow-up and was not included in the data. 30 were enrolled and 29 completed the study and included in the data.

Age, Continuous
Age, Continuous(Years)Total - All Participants, Combined Across Treatment Sequences
Mean53.9 ± 5.5
Sex: Female, Male
Sex: Female, Male(Participants)Total - All Participants, Combined Across Treatment Sequences
Female13
Male16
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Total - All Participants, Combined Across Treatment Sequences
Region of Enrollment
Region of Enrollment(participants)Total - All Participants, Combined Across Treatment Sequences
United States29
08

Study locations

1 site
  • Bausch and Lomb
    Rochester, New York 14609, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Mar 2022, 1 month.

Results were first posted in Aug 2026, 4 years 4 months after primary completion.

Of 89 industry-sponsored interventional studies with no phase under Presbyopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 22. This study's 1 month is below that.

Counting every sponsor, half of 131 studies reached it within 11 months; a quarter within 3 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2022
First posted
Apr 13, 2022
StartActual
Feb 25, 2022
Primary completionActual
Mar 28, 2022
CompletionActual
Mar 28, 2022
Results first posted
Aug 6, 2026
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05325931
Responsible party
Sponsor
First posted
Apr 13, 2022
Start date
Feb 25, 2022
Primary completion
Mar 28, 2022
Completion
Mar 28, 2022
Results posted
Aug 6, 2026
Last update
Aug 6, 2026

Study contacts

Jeffery Schafer
study director · Bausch & Lomb Incorporated

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion